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Fig 2. Cumulative incidence of relapse among pts in MRNeg CR1 (competing
risk is death before relapse).
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Background: Allogeneic HCT is used commonly in adults
with ALL. MRD is an accepted prognostic factor in ALL. Being
MRD-negative (MRDNeg) overcomes age and cytogenetics
(CG; Bassan, Blood, 2009), and it is predictive of outcome
without (No) HCT and prior to myeloablative (MAC) and
reduced-intensity HCT (RIC). However, comparisons of these
treatments in this favorable-risk subgroup are limited. We
sought to examine outcomes with these 3 approaches
exclusively in pts in ﬁrst MRDNeg remission (MRDNeg CR1).
Methods: We performed a retrospective analysis of pts that
were diagnosed or referred for HCT at our Center since 2005.
MRDNeg was deﬁned as undetectable by all methods used:
Multiparameter ﬂow cytometry was used in all pts, though
other measures (PCR, FISH, and/or CG) were considered if
performed. Clinical risk factors at diagnosis (dx) included age
 35, high white blood count (WBC; > 30 in B-ALL, > 100 in
T-ALL), and adverse CG (Ph+, low hypodiploid/near triploid,
complex [ 5 abnormalities], MLL rearranged, t[8;14], -7, and
+8). Group characteristics were compared with Fisher’s exact
test. Kaplan-Meier plots and Cox proportional hazardmodels
were used to investigate associations between variables.
Results: Of 127 pts identiﬁed, 53 (42%) received MAC, 19
(15%) received RIC, and 55 (43%) No HCT while in MRDNeg
CR1. RIC pts were signiﬁcantly more likely than MAC and No
HCT pts to be  35 years old at dx (89% vs 60% vs 51%,
respectively [resp.]; P¼ 0.0084) and have adverse CG (83% vs
53% vs 30%, resp.; P < 0.001). There were no signiﬁcant dif-
ferences inWBC at dx, initial therapy received, or (among the
HCT groups) stem-cell donor or product. All Ph+ pts received
tyrosine kinase inhibitors.
Overall survival (OS) from dx in these 3 groups was
similar (P¼ 0.35; Fig 1), though relapse was signiﬁcantly less
with MAC (P ¼ 0.01; Fig 2). 3-year (yr) estimates of OS with
MAC, RIC, and No HCT were 71%, 73%, and 75% (resp.), and
30%, 51%, and 60% (resp.) for relapse. 3-yr non-relapse mor-
tality was 17% with MAC vs 5% with RIC (P¼ 0.15). Compared
to No HCT, the risk of death was not different with MACFig 1. OS from diagnosis among pts in MRDNeg CR1.(hazard ratio [HR] 1.6, P ¼ 0.19) or RIC (HR 1.0, P ¼ 1.0),
adjusted for WBC. However, relapse was lower with HCT,
adjusted for WBC and (due to more events) adverse CG:
signiﬁcantly so after MAC (HR 0.35, P ¼ 0.0014) but not with
RIC (HR 0.57, P ¼ 0.18). OS was also similar with Ph+ and Ph-
studied separately (P ¼ 0.99 and 0.14, resp.).
In a distinct analysis of 23 pts who underwent HCT while
MRDNeg beyond CR1 (CR2+), OS from HCT was comparable
for CR1 and CR2+ (P ¼ 0.46). 3-yr estimates of OS were 69%
and 62% (resp.).
Conclusions: Among contemporary adults with ALL in
MRDNeg CR1, RIC pts were more commonly older with
adverse CG. MAC yielded signiﬁcantly less relapse, but OS
was no different thanwith RIC or No HCT. HCT while MRDNeg
yields similar outcomes in CR1 and CR2+. For pts in MRDNeg
CR1, the role of up-front HCT is less clear.
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Introduction: FLT3mutations are present inup to30%ofAML
pts with diploid cytogenetics. Allogeneic hematopoietic stem
cell transplantation (AlloSCT) has emerged as the preferred
therapy for this high-risk group, but these pts remain at high
risk for disease relapse. The signiﬁcance of FLT3 detection by
PCR, as a minimal residual disease marker, at the time of
AlloSCT remains unclear and little is known about the risk
factors associated with risk of relapse among FLT3 AML pts.
Methods: We reviewed 1255 AML pts who underwent ﬁrst
AlloSCT between 2000 and 2014, and identiﬁed 200 adult pts
with a FLT3-ITD or FLT3-TKD mutation found at diagnosis
Table 1
Sex (M/F) 98/102
Median age 51 (18-72)
Age > 50 53%
KPS > 80% 64%
HCT-CI Score >4 19%
Figure 1A. Progression-free survival.
Figure 1B. Cumulative incidence of relapse for FiT3+ve pts by disease status at
transplant.
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sibling (MSD), 95 10/10 MUD, 11 9/10 MUD, 18 cord blood
(CB), and 13 haploidentical (Haplo).
Results: The majority of pts received myeloablative condi-
tioning (n¼170; busulfan-based n¼148). Disease status at
AlloSCT was: CR1 (n¼99), CR2 (n¼20), CR with incomplete
count recovery or hypoplasticmarrowor CR3 (CRi; n¼31), and
active disease (AD; n¼50). Thirty percent of pts received a FLT3
inhibitorbeforeAlloSCT.After amedian follow-upof27mo, the
2-year (2Y) OS and PFS rates were 43% and 41%, respectively.
Relapse-related mortality was the main cause of death (68%).
Remission and FLT3 status at the time of AlloSCT were signiﬁ-
cantly associated with PFS. Compared to CR1 pts, PFS was not
different inCR2 [HR1.5, p¼0.3], but itwasworse inCRi (HR3.9,
p<0.001)andADpts (HR5.9, p<0.001). The2YPFSwashighest
inCR1/2FLT3evepts (62%) compared to theothergroups:CR1/
2 FLT3+ve (41%, p¼0.3); CRi FLT3eve (33%, p¼0.01); CRi
FLT3+ve (0%, p<0.001); AD (8% p<0.001) (Figures 1A, 1B). On
multivariate analysis, independent predictors of worse PFS
included: AD [HR 4.5, p<0.001], CRi FLT3+ve [HR 7.2,
p<0.001], KPS80 [HR2.1, p<0.001], HCT-CI>4 [HR 1.6,
p¼0.05], and unrelated donor source [HR 1.6, p¼0.05]. No
difference in PFS was found between Haplo and MSD donor
sources (HR¼0.9, p¼0.9). No signiﬁcant association wasidentiﬁed by age, conditioning intensity or use of a FLT3
inhibitor prior to transplant. Post-transplant FLT3 status was
available for 105 of 190 evaluable pts by day 30. Among
them, 7ptshaddetectable FLT3PCR and5/7 pts (71%) relapsed.
Conclusion: Morphologic remission and FLT3 PCR status at
the time of transplant are key predictors of relapse risk in pts
with FLT3+ AML. Patients who achieved a morphologic CR
with an undetectable FLT3 by PCR at the time of SCT had the
best outcomes and should undergo an AlloSCTwithout delay.
Although the experience is limited, Haplo transplants had
similar outcomes to MSD transplants. Prospective clinical
trials with FLT3 inhibitors post-transplant are warranted at
least for pts with AD or persistent FLT3+ on PCR at transplant.
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Introduction: There are limited data on the impact of he-
matopoietic stem cell transplant (HSCT) conditioning
regimen, especially without total body radiation (TBI) in
pediatric patients with acute lymphoblastic leukemia (ALL)
with central nervous system (CNS) involvement. The aim of
this study is compare the results of HSCT using non-TBI
conditioning regimen in ALL patients aged18 years with or
without CNS involvement.
Patients and Methods: Records of 183 patients with ALL
(128 male; 55 female) with a median age of 14.13.7 years
who had undergone HSCT were studied and classiﬁed in two
groups: with and without CNS involvement. Long-term
consequence of the HSCT consisting of leukemia free survival
(LFS), the overall survival (OS), relapse and transplant-
related mortality (TRM) was compared in the two groups.
Results: A total of 183 ALL patients (148 without CNS
involvement and 35 with CNS involvement) underwent
HSCT in our center using a TBI-free conditioning containing
Busulfan and Cyclophosphomide. The median time of follow
up was 42.1 months. Estimated probability on relapse at 4
year was 51.4% in patients with CNS involvement and 42.1%
in patients without CNS involvement (p¼0.588). Regarding
survival analysis, 4-year OS and LFS in all patients was 44.4%
(SE:2.5%) and 39.7%(SE:2.5%). In multivariate analysis there
were no signiﬁcant differences in OS and LFS between two
groups (p¼0.839, p¼894) nor was there a difference in
relapse probability (HR:1.20, 95%CI:0.69-2.1, p¼0.513) and
TRM (HR:0.44, 95%CI:0.10-1.92, p¼0.286).
Conclusion: HSCT using a non TBI conditioning regimen in
ALL are similar with studies using TBI containing regimens.
Furthermore HSCT leads to similar clinical outcomes and
long-term survival in the ALL pediatric patients with or
without CNS involvement.
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